While maintaining its 'neutral' position on Sartorius Stedim Biotech, UBS has raised its price target from €260 to €265, a target that implies a 10% growth potential for the pharmaceutical supplier's stock.

While the strong upturn in order intake in the fourth quarter is 'encouraging', and medium-term organic growth supports the current valuation, the broker considers upside potential to be 'limited'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.